Assistant Director of Drugs Control in Zone-V, Chennai, has temporarily suspended the drug license of CPD Pharma Private Limited, a company wholly owned by Entero Healthcare Solutions Limited.
The suspension is for seven days, from February 26, 2024, to March 3, 2024, due to violations of Section 18(c) of the Drugs and Cosmetics Act, 1940, along with Rule 65(9)(b) of Drugs and Cosmetics Rules, 1945, and the license conditions.
The violation is related to Section 18(c) of the Drugs and Cosmetics Act 1940 and Rule 65(9)(b) of Drugs and Cosmetic Rules 1945, in connection with CPD’s business activities.
The impact on Entero’s financial and operational activities is minimal. CPD’s operations were already downsized for operational efficiency in the region, with external customer supplies discontinued after January 31, 2024.
CPD’s revenue contributes only 0.17% (excluding intercompany sales) to Entero’s total consolidated revenue as of the half-year ending September 30, 2023.
Stay informed with our financial updates, stocks, bonds, commodities. Get global & political insights. Follow us & enable notifications for the latest updates.
